{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:04:34Z","timestamp":1790949874412,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":582,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1111\/jth.15247","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T13:17:20Z","timestamp":1611667040000},"page":"909-916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Von Willebrand disease type 2N: An update"],"prefix":"10.1016","volume":"19","author":[{"given":"Omid","family":"Seidizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Mannuccio","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.15247_bb0010","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.cb.06.110190.001245","article-title":"Cell biology of von Willebrand factor","volume":"6","author":"Wagner","year":"1990","journal-title":"Annu Rev Cell Biol"},{"issue":"Suppl 2","key":"10.1111\/jth.15247_bb0015","first-page":"s3","article-title":"Role of von Willebrand factor in the haemostasis","volume":"9","author":"Peyvandi","year":"2011","journal-title":"Blood Transfus"},{"key":"10.1111\/jth.15247_bb0020","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand's disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15247_bb0025","first-page":"337","article-title":"Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology","volume":"14","author":"Mazurier","year":"2001","journal-title":"Clin Haematol"},{"key":"10.1111\/jth.15247_bb0030","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1365-2141.1990.tb06371.x","article-title":"Evidence for a von Willebrand factor defect in factor VIII binding in three members of a family previously misdiagnosed mild haemophilia A and haemophilia A carriers: consequences for therapy and genetic counselling","volume":"76","author":"Mazurier","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15247_bb0035","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/MBC.0000000000000932","article-title":"Are Iranian patients with von Willebrand disease type 2N properly differentiated from hemophilia A and do they receive appropriate treatment?","volume":"31","author":"Seidizadeh","year":"2020","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.15247_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2009.02005.x","article-title":"Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance","volume":"16","author":"Terraube","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15247_bb0045","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2014-05-378638","article-title":"von Willebrand factor, Jedi knight of the blood\u2010stream","volume":"124","author":"Springer","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.15247_bb0050","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood-2015-04-641688","article-title":"Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry","volume":"126","author":"Chiu","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.15247_bb0055","doi-asserted-by":"crossref","first-page":"21948","DOI":"10.1016\/S0021-9258(18)54729-3","article-title":"The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII","volume":"266","author":"Wise","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15247_bb0060","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2012-01-405134","article-title":"Sequence and structure relationships within von Willebrand factor","volume":"120","author":"Zhou","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.15247_bb0065","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/S0021-9258(18)47430-3","article-title":"A major factor VIII binding domain resides within the amino\u2010terminal 272 amino acid residues of von Willebrand factor","volume":"262","author":"Foster","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.15247_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0049-3848(87)90417-8","article-title":"Evidence that NH2\u2010terminal but not COOH\u2010terminal moiety of plasma von Willebrand factor binds to factor VIII","volume":"48","author":"Jorieux","year":"1987","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15247_bb0075","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0006-291X(89)92182-7","article-title":"Localization within the 106 N\u2010terminal amino acids of von Willebrand factor (vWF) of the epitope corresponding to a monoclonal antibody which inhibits vWF binding to factor VIII","volume":"163","author":"Pietu","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"issue":"16","key":"10.1111\/jth.15247_bb0080","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2016-04-713289","article-title":"Life in the shadow of a dominant partner: the FVIII\u2010VWF association and its clinical implications for hemophilia A","volume":"128","author":"Pipe","year":"2016","journal-title":"Blood"},{"key":"10.1111\/jth.15247_bb0085","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2141.1982.tb03888.x","article-title":"Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease","volume":"52","author":"Tuddenham","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15247_bb0090","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2141.1994.tb05127.x","article-title":"Biological effect of desmopressin in eight patients with type 2N (\u2018Normandy\u2019) von Willebrand disease. Collaborative Group","volume":"88","author":"Mazurier","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15247_bb0095","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0049-3848(99)00123-1","article-title":"Effect of von Willebrand Factor and its proteolytic fragments on kinetics of interaction between the light and heavy chains of human factor VIII","volume":"96","author":"Saenko","year":"1999","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15247_bb0100","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1538-7836.2007.02572.x","article-title":"Clearance mechanisms of von Willebrand factor and factor VIII","volume":"5","author":"Lenting","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15247_bb0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2516.2007.01484.x","article-title":"Immune tolerance induction with a high purity von Willebrand factor\/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response","volume":"13","author":"Gringeri","year":"2007","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15247_bb0110","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1182\/blood.V74.5.1591.1591","article-title":"New variant of von Willebrand disease with defective binding to factor VIII","volume":"74","author":"Nishino","year":"1989","journal-title":"Blood"},{"key":"10.1111\/jth.15247_bb0115","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood.V75.1.20.20","article-title":"A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF\/FVIII interaction","volume":"75","author":"Mazurier","year":"1990","journal-title":"Blood"},{"key":"10.1111\/jth.15247_bb0120","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/MBC.0b013e328332d022","article-title":"Identification and prevalence of von Willebrand disease type 2N (Normandy) in Australia","volume":"20","author":"Favaloro","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.15247_bb0125","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/hae.13366","article-title":"Type 2N von Willebrand disease: characterization and diagnostic difficulties","volume":"24","author":"Casonato","year":"2018","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15247_bb0130","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2516.2007.01623.x","article-title":"A web\u2010based registry of inherited bleeding disorders in the region of Emilia\u2010Romagna: results at three and a half years","volume":"14","author":"Tagliaferri","year":"2008","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15247_bb0135","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2516.2008.01679.x","article-title":"Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis","volume":"14","author":"Iorio","year":"2008","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15247_bb0140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/01.mbc.0000198048.42634.5a","article-title":"Use of a new enzyme\u2010linked immunosorbent assay for the detection of type 2N von Willebrand disease and its prevalence in an Indian population","volume":"17","author":"Ghosh","year":"2006","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.15247_bb0145","first-page":"55","article-title":"Type 2N von Willebrand disease (Normandy)","volume":"46","author":"Morales\u2010De la Vega","year":"2008","journal-title":"Revista M\u00e9dica del Instituto Mexicano del Seguro Social"},{"key":"10.1111\/jth.15247_bb0150","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/1076029606299000","article-title":"Identifying carriers of type 2N von Willebrand disease: procedures and significance","volume":"13","author":"Casonato","year":"2007","journal-title":"Clin Appl Thromb Haemost"},{"key":"10.1111\/jth.15247_bb0155","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s12185-014-1662-3","article-title":"Life\u2010threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N","volume":"100","author":"Allan","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1111\/jth.15247_bb0160","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/pbc.25054","article-title":"Co\u2010inheritance of mild hemophilia A and heterozygosity for type 2N von Willebrand disease: a diagnostic and therapeutic challenge","volume":"61","author":"Lindsay","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/jth.15247_bb0165","first-page":"1110","article-title":"Combined hemophilia A and type 2 von Willebrand's disease: defect of both factor VIII level and factor VIII binding capacity of von Willebrand factor","volume":"86","author":"Casonato","year":"2001","journal-title":"Haematologica"},{"key":"10.1111\/jth.15247_bb0170","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MBC.0000000000000067","article-title":"Spontaneous hemarthrosis in combined Glanzmann thrombasthenia and type 2N von Willebrand disease","volume":"25","author":"Pontara","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.15247_bb0175","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1111\/hae.12595","article-title":"VWD type 2N (Normandy) in two sisters","volume":"21","author":"Agne","year":"2015","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15247_bb0180","doi-asserted-by":"crossref","first-page":"e375","DOI":"10.1111\/hae.12733","article-title":"Clinical phenotype in genetically confirmed von Willebrand disease type 2N patients reflects a haemophilia A phenotype","volume":"21","author":"van Meegeren","year":"2015","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15247_bb0185","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2516.2011.02617.x","article-title":"The natural history of mild haemophilia: a 30\u2010year single centre experience","volume":"18","author":"Tagliaferri","year":"2012","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15247_bb0190","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.thromres.2019.07.010","article-title":"How we make an accurate diagnosis of von Willebrand disease","volume":"196","author":"Baronciani","year":"2020","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15247_bb0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2516.2008.01849.x","article-title":"Diagnosis of von Willebrand disease subtypes: implications for treatment","volume":"14","author":"Budde","year":"2008","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15247_bb0200","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/hae.12380","article-title":"Diagnosis of inherited von Willebrand disease: comparison of two methodologies and analysis of the discrepancies","volume":"20","author":"Costa\u2010Pinto","year":"2014","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15247_bb0205","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2516.2009.01995.x","article-title":"Measurement of von Willebrand factor\u2010FVIII binding activity in patients with suspected von Willebrand disease type 2N: application of an ELISA\u2010based assay in a reference laboratory","volume":"15","author":"Zhukov","year":"2009","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15247_bb0210","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1365-2516.2011.02499.x","article-title":"Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis","volume":"17","author":"Veyradier","year":"2011","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15247_bb0215","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood-2014-08-528398","article-title":"Diagnostic approach to von Willebrand disease","volume":"125","author":"Ng","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.15247_bb0220","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/bjh.14028","article-title":"von Willebrand disease type1\/type 2N compound heterozygotes: diagnostic and management challenges","volume":"176","author":"Perez Botero","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15247_bb0225","first-page":"959","article-title":"Characterisation of type 2N von Willebrand disease using phenotypic and molecular techniques","volume":"76","author":"Nesbitt","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15247_bb0230","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/asheducation-2016.1.678","article-title":"Diagnosing von Willebrand disease: genetic analysis","volume":"2016","author":"Goodeve","year":"2016","journal-title":"Hematology"},{"key":"10.1111\/jth.15247_bb0235","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/hae.13175","article-title":"Molecular diagnosis of von Willebrand disease","volume":"23","author":"Baronciani","year":"2017","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15247_bb0240","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/bjh.12249","article-title":"The molecular characterization of von Willebrand disease: good in parts","volume":"161","author":"James","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15247_bb0245","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood-2002-04-1046","article-title":"An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant","volume":"101","author":"Casonato","year":"2003","journal-title":"Blood"},{"key":"10.1111\/jth.15247_bb0250","first-page":"290","article-title":"Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide","volume":"3","author":"Hilbert","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15247_bb0255","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1160\/TH04-02-0084","article-title":"Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization","volume":"92","author":"Schneppenheim","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15247_bb0260","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood.V95.10.3139","article-title":"Conformational changes in the D\u2032 domain of von Willebrand factor induced by CYS 25 and CYS 95 mutations lead to factor VIII binding defect and multimeric impairment","volume":"95","author":"Jorieux","year":"2000","journal-title":"Blood"},{"key":"10.1111\/jth.15247_bb0265","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1365-2141.2004.05187.x","article-title":"INSERM Network on Molecular Abnormalities in von Willebrand Disease. Expression of two type 2N von Willebrand disease mutations identified in exon 18 of von Willebrand factor gene","volume":"127","author":"Hilbert","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15247_bb0270","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1046\/j.1365-2141.2003.04163.x","article-title":"Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII\u2010binding capacity","volume":"120","author":"Hilbert","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.15247_bb0275","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2013-07-517086","article-title":"Solution structure of the major factor VIII binding region on von Willebrand factor","volume":"123","author":"Shiltagh","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.15247_bb0280","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1042\/BCJ20180431","article-title":"The D\u2032 domain of von Willebrand factor requires the presence of the D3 domain for optimal factor VIII binding","volume":"475","author":"Przeradzka","year":"2018","journal-title":"Biochem J"},{"issue":"04","key":"10.1111\/jth.15247_bb0285","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1055\/s-0039-3402430","article-title":"Genetic background of von Willebrand disease: history, current state, and future perspectives","volume":"46","author":"Zolkova","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.15247_bb0290","series-title":"von Willebrand Disease. GeneReviews\u00ae [Internet]","author":"Goodeve","year":"2017"},{"key":"10.1111\/jth.15247_bb0295","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1055\/s-0031-1281031","article-title":"The International Society on thrombosis and haemostasis von Willebrand disease database: an update","volume":"37","author":"Hampshire","year":"2011","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.15247_bb0300","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1182\/blood-2011-10-384610","article-title":"VWF mutations and new sequence variations identified in healthy controls are more frequent in the African\u2010American population","volume":"119","author":"Bellissimo","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.15247_bb0305","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000214852","article-title":"Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1","volume":"121","author":"Michiels","year":"2009","journal-title":"Acta Haematol"},{"key":"10.1111\/jth.15247_bb0310","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1538-7836.2003.00190.x","article-title":"Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP)","volume":"1","author":"Kaufmann","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15247_bb0315","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years","volume":"90","author":"Mannucci","year":"1997","journal-title":"Blood"},{"key":"10.1111\/jth.15247_bb0320","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1111\/jth.13491","article-title":"Advances in the treatment of bleeding disorders","volume":"14","author":"Peyvandi","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15247_bb0325","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/blood.V97.7.1915","article-title":"How I treat patients with von Willebrand disease","volume":"97","author":"Mannucci","year":"2001","journal-title":"Blood"},{"key":"10.1111\/jth.15247_bb0330","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2003-06-2072","article-title":"Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study","volume":"103","author":"Federici","year":"2004","journal-title":"Blood"},{"key":"10.1111\/jth.15247_bb0335","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1182\/blood.V92.12.4663","article-title":"A novel mutation in the D3 domain of von Willebrand factor markedly decreases its ability to bind factor VIII and affects its multimerization","volume":"92","author":"Jorieux","year":"1998","journal-title":"Blood"},{"key":"10.1111\/jth.15247_bb0340","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/jth.13749","article-title":"Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice","volume":"15","author":"Swystun","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15247_bb0345","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/asheducation-2017.1.379","article-title":"Advances in the diagnosis and treatment of Von Willebrand disease","volume":"2017","author":"Sharma","year":"2017","journal-title":"Hematology"},{"issue":"126","key":"10.1111\/jth.15247_bb0350","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease","volume":"22","author":"Gill","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.15247_bb0355","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra040403","article-title":"Treatment of von Willebrand's disease","volume":"351","author":"Mannucci","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.15247_bb0360","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 Fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"Konkle","year":"2020","journal-title":"N Engl J Med"},{"issue":"198","key":"10.1111\/jth.15247_bb0365","first-page":"7","article-title":"Activated factor VIII\u2010mimicking effect by emicizumab on thrombus formation in type 2N von Willebrand disease under high shear flow conditions","volume":"22","author":"Yaoi","year":"2020","journal-title":"Thromb Res"},{"key":"10.1111\/jth.15247_bb0370","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/pbc.23120","article-title":"Therapeutic consequences for misdiagnosis of type 2N von Willebrand disease","volume":"57","author":"Gupta","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/jth.15247_bb0375","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0925-5710(96)00470-7","article-title":"Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy","volume":"64","author":"Nishino","year":"1996","journal-title":"Int J Hematol"},{"key":"10.1111\/jth.15247_bb0380","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1538-7836.2005.01162.x","article-title":"Pregnancy and delivery in patients with homozygous or heterozygous R854Q type 2N von Willebrand disease","volume":"3","author":"Castaman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15247_bb0385","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1055\/s-0037-1613249","article-title":"First Italian families with homozygous R854Q type 2 N von Willebrand disease","volume":"88","author":"Castaman","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.15247_bb0390","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3324\/haematol.2009.011239","article-title":"Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor mutations","volume":"95","author":"Castaman","year":"2010","journal-title":"Haematologica"},{"key":"10.1111\/jth.15247_bb0395","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0029-7844(97)81431-7","article-title":"Successful management of pregnancy in a patient with von Willebrand disease Normandy","volume":"89","author":"Watanabe","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1111\/jth.15247_bb0400","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1046\/j.1365-2516.2000.00428.x","article-title":"Unexpected presentation of type 2N von Willebrand disease in pregnancy","volume":"6","author":"Dennis","year":"2000","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15247_bb0405","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1111\/hae.13481","article-title":"Management of pregnancy complications in type 2N von Willebrand disease associated to a novel mutation","volume":"24","author":"Brennan","year":"2018","journal-title":"Haemophilia"},{"key":"10.1111\/jth.15247_bb0410","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.siny.2011.07.006","article-title":"Management of pregnancy and delivery in women with inherited bleeding disorders","volume":"16","author":"Peyvandi","year":"2011","journal-title":"Semin Fetal Neonatal Med"},{"key":"10.1111\/jth.15247_bb0415","first-page":"e193","article-title":"Management of inherited bleeding disorders in pregnancy. Green\u2010top guideline no. 71","volume":"124","author":"Pavord","year":"2017","journal-title":"BJOG"},{"key":"10.1111\/jth.15247_bb0420","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1538-7836.2005.01150.x","article-title":"von Willebrand disease and pregnancy","volume":"3","author":"Kujovich","year":"2005","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15247","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15247","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622007279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622007279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:31:22Z","timestamp":1761535882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622007279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1538783622007279"],"URL":"https:\/\/doi.org\/10.1111\/jth.15247","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Von Willebrand disease type 2N: An update","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}